Last update 06 Dec 2024

Mocetinostat Dihydrobromide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mocetinostat, Mocetinostat dihydrobromide (USAN), 726169-73-9
+ [4]
Mechanism
HDAC1 inhibitors(Histone deacetylase 1 inhibitors), HDAC11 inhibitors(histone deacetylase 11 inhibitors), HDAC2 inhibitors(Histone deacetylase 2 inhibitors)
Therapeutic Areas
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC23H22Br2N6O
InChIKeyACPWZKZFDFBALX-UHFFFAOYSA-N
CAS Registry944537-89-7

External Link

KEGGWikiATCDrug Bank
D09357--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 2
US
07 Nov 2016
Advanced cancerPhase 2
US
01 Jun 2016
Advanced Malignant Solid NeoplasmPhase 2
US
01 Jun 2016
Metastatic urothelial carcinomaPhase 2
US
01 Oct 2014
Urothelial Carcinoma of the Urinary BladderPhase 2
US
01 Oct 2014
Bladder CancerPhase 2
US
10 Sep 2014
Follicular LymphomaPhase 2
US
01 Oct 2007
Non-Hodgkin's lymphoma refractoryPhase 2
US
01 Oct 2007
Chronic lymphocytic leukaemia refractoryPhase 2
US
01 Jan 2007
Chronic lymphocytic leukaemia refractoryPhase 2
CA
01 Jan 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
161
ofhtyadhcc(ofscchuyii) = ojdarsrcbb vghwtyoolk (rkqnxdcnto, tmqeqpynkl - ohffxprqkh)
-
22 Apr 2024
Phase 1/2
7
pqynrynmpk(cyjqufkqqy) = bycwvzczkf byiefgyfmf (urctcuaruu, lgnberezcj - ufufrzehgk)
-
08 Mar 2024
Phase 1
7
xbxvvhacqa(idlsfwipia) = The only grade 3 or 4 treatment related AEs were neutropenia, lymphopenia and anemia. nvvzqlkfjd (daxpyugybk )
Positive
02 Jun 2022
Phase 2
17
rdxxojxqfm(bzspgqpeli) = nausea (77%) and fatigue (71%) gjjniikrsi (wbomaemmqm )
Negative
15 Feb 2019
Phase 2
20
tqahqusulj(ftfebvcqpp) = kyidxcvgxl otzgmrntvw (kicpbduulk, cgupwwnmet - imnspnatox)
-
29 Jan 2019
Phase 1/2
48
gemcitabine+mocetinostat
(Phase I)
woztrfhzyt(hmyurvaxsp) = Grade ≥ 3 treatment-related adverse events (AEs) were reported by 81% of all patients, the most frequent being fatigue (38%) and thrombocytopenia (19%). wimukptlyv (stqipgnyyw )
Negative
01 Feb 2018
gemcitabine+mocetinostat
(Phase II)
Phase 2
69
wwoadkmprk(ycxflfjokp) = 4 each gnmkrpypph (rcqgqqbhnq )
-
20 May 2013
Phase 2
20
dmmsoiaftj(xeudjyiyue) = bozzvdayqj ngobvxkdcv (xzhuvqtlcf )
-
20 May 2013
Phase 2
51
(esuzvksmlo) = zdnfzbevau ghgaoollnm (pqjkzyaztm )
Positive
01 Dec 2011
Phase 2
28
equpamapmf(xdnfgpryft) = Pericardial SAEs were observed in other MGCD0103 trials and hence the studies were voluntarily suspended for further investigation. In total, 437 patients have been treated with MGCD0103. There were 19 patients (4.3%) with a SAE where one of the listed terms involved the pericardium. Patients with Hodgkin Lymphoma were more likely (9.5%) to experience a pericardial SAE as compared to other diagnosis, while patients with solid tumors had an incidence of only 0.9%. Most pericardial SAEs (14) occurred during Cycle 1 of treatment. There were no clear relationships with the starting dose level, exposure, cumulative dose, drug lots, prior history of chest pain/arrhythmia or other cardiac diseases, prior therapies, prior mediastinal or thoracic radiotherapy, presence of mediastinal lesions, PD markers of HDAC activity or inflammation, low albumin levels at baseline, pneumonia, sepsis or infection. Statistically significant associations were found with patients who had a history of pericardial disease, presence of lung lesions, and on-study reports of chest pain or pleural effusion. fylpjzoefz (kbdtcbmjhl )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free